Tafenoquine/Chloroquine DDI Study

Malaria Clinical Trial

Official title:

Safety, Tolerability, and Pharmacokinetic Study of Concomitant Chloroquine and Tafenoquine in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00871156
• Other study ID #: 106491
• Status: Completed
• Phase: Phase 1
• First received: March 23, 2009
• Last updated: June 16, 2017
• Start date: March 24, 2009
• Est. completion date: August 26, 2009

Study information

• Verified date: June 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

DDI study of Tafenoquine and Chloroquine

Description:

Safety, Tolerability, and Pharmacokinetic Study of Concomitant Chloroquine and Tafenoquine in Healthy Volunteers

Recruitment information / eligibility

• Status: Completed
• Enrollment: 68
• Est. completion date: August 26, 2009
• Est. primary completion date: August 26, 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and ECGs. A subject with a clinical abnormality or laboratory parameters outside the reference range may be included only if the Investigator and GSK medical monitor agree that the abnormality will not introduce additional risk factors and will not interfere with the study procedures.

• Male or female between 18 and 55 years of age inclusive, at the time of signing the informed consent.

• A female subject is eligible to participate if she is of non-childbearing potential or of child-bearing potential if has a negative urine pregnancy test at screening and Day -1, and agrees to use agreed upon contraception methods until 56 days after stopping study drug.

• Body weight >=60 kg (132 pounds) and BMI within the range 19-32 kg/m2 (inclusive).

• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form

Exclusion Criteria:

• A positive urine drug/alcohol screen at screening or Day -1.

• History or regular use of tobacco- or nicotine-containing products within 3 months prior to screening.

• History of illicit drug abuse within 6 months prior to screening.

• History of regular alcohol consumption within 6 months of the study

• Subjects who are unwilling to comply with the lifestyle guidelines required.

• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).

• Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.

• History of sensitivity to any of the study medications or their components.

• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.

• Pregnant females as determined by positive urine hCG test at screening or prior to dosing.

• Lactating females.

• Subject is mentally or legally incapacitated.

• A positive HIV antibody, Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.

• The subject's systolic blood pressure is outside the range of 90-150mmHg or diastolic blood pressure is outside the range of 45-90mmHg or heart rate is outside the range of 50-100bpm for female subjects and 45-100bpm for male subjects at screening and Day -1.

• Cardiac conduction abnormalities as specified inprotocol

• Any significant arrhythmia which, in the opinion of the principal investigator and GSK medical monitor, will interfere with the safety for the individual subject.

• History of angina, ischemic heart disease, myocardial infarction, or clinically significant arrhythmia.

• History of epilepsy, convulsions or psychological disorders.

• History of porphyria.

• AST, ALT or alkaline phosphatase >1.5 times the upper limit of normal and/or total bilirubin level outside the normal range at screening. A single repeat is allowed for eligibility determination.

• Documented Glucose-6-phosphate dehydrogenase (G6PD) deficiency, determined by a quantitative assay of enzyme activity.

• History of hemoglobinopathy; or current or past history of methemoglobinemia or methemoglobin percentage above the reference range at screening.

• History of previous eye surgery involving the retina, Lasik surgery within 90 days, or retinal/corneal abnormalities.

• Any clinically significant abnormalities on the screening Humphrey 10-2 visual field test.

• Best corrected visual acuity worse than 0.3 logMAR (20/40 Snellen equivalent) (i.e., 20/40 or better vision will be allowed on study).

Related Conditions & MeSH terms

• Malaria

Intervention

Drug:
• Chloroquine, Tafenoquine
Chloroquine and Tafenoquine
• Placebo
Placebo

Locations

Country	Name	City	State
United States	GSK Investigational Site	Buffalo	New York

Sponsors (2)

Lead Sponsor	Collaborator
GlaxoSmithKline	Medicines for Malaria Venture

Country where clinical trial is conducted

United States, 

References & Publications (1)

Miller AK, Harrell E, Ye L, Baptiste-Brown S, Kleim JP, Ohrt C, Duparc S, Möhrle JJ, Webster A, Stinnett S, Hughes A, Griffith S, Beelen AP. Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects. Br J Clin Pharmacol. 2013 Dec;76(6):858-67. doi: 10.1111/bcp.12160. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	TQ and Chloroquine (Day 2): AUC(0-tau), Cmax and Tmax		56 days
Primary	CQ and TQ (Day 3): AUC(0-tau), AUC(0-inf), Cmax, Tmax and t1/2		56 days
Primary	AEs, vital signs, 12-lead ECGs, telemetry, clinical laboratory and ophthalmic assessments		56 days
Secondary	QTcF, QT, QRS, RR and HR as assessed by 12-lead ECG		56 Days
Secondary	Changes from baseline in QTcF		56 days

External Links

•   Results for study 106491 can be found on the GSK Clinical Study Register.